Secukinumab: In psoriasis and beyond
Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behç...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of the Egyptian Women’s Dermatologic Society |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jewd.jewd_80_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|